ThinkEquity Upgrades Anadys Pharma (ANDS) to Buy
More News related to ANDS
- Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
- Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
- National Securities Initiates Coverage on Anadys Pharmaceuticals (ANDS) with a Buy
More News related to Upgrades
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
ThinkEquity upgrades Anadys Pharma (Nasdaq: ANDS) from Accumulate to Buy with a $6 price target.
For more analyst ratings on ANDS click here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
Related Categories
UpgradesStocks Mentioned
+0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
